Trial Profile
A Phase IB/II Rescue Study With Azacitidine, Durvalumab (MEDI4736), and Tremelimumab Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Durvalumab (Primary)
- Indications Head and neck cancer
- Focus First in man; Therapeutic Use
- 07 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2025.
- 18 Oct 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2023.
- 17 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jul 2023.